
Annexon, Inc (ANNX) Stock Forecast & Price Target
Annexon, Inc (ANNX) Analyst Ratings
Bulls say
Annexon is a promising biotech company with a strong focus on developing C1q inhibitors for geographic atrophy, a challenging market but with potential for significant sales. The company's current main goal is to achieve vision restoration in GA, with their new drug ANX1502 showing promise in reducing complement activity and having mild side effects. However, profitability may take several years and additional funding, but the company has potential for success with potential for combination treatments and advancements in gene therapy, stem cell therapy, and local delivery of medication to the eye.
Bears say
Annexon is facing potential challenges with its drug candidates, particularly in regards to safety and efficacy concerns. Its financial status and upcoming trials will be crucial in determining the success of its pipeline, but it remains to be seen if these drugs will become market leaders and have a significant impact on the medical community. Given these uncertainties and potential hurdles, a negative outlook is warranted for Annexon's stock.
This aggregate rating is based on analysts' research of Annexon, Inc and is not a guaranteed prediction by Public.com or investment advice.
Annexon, Inc (ANNX) Analyst Forecast & Price Prediction
Start investing in Annexon, Inc (ANNX)
Order type
Buy in
Order amount
Est. shares
0 shares